secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2026-07-01T20:08:37+00:00
Accession:  0000875045-26-000068
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Biogen expects Q2 IPR&D charge of ~$164M ($0.95/share) and Q3 charge of $290M-$320M ($1.75-$1.95/share)
--------------------------------------------------------------------------------

- Q2 2026: ~$164M pre-tax IPR&D charge; EPS impact ~$0.95 per share.
- Q3 2026: $290M-$320M pre-tax IPR&D charge; EPS impact $1.75-$1.95 per share.
- Charges relate to collaboration and license agreements, including upfront and milestone payments.
- Results for Q2 2026 not finalized; subject to financial closing procedures.
- Company does not forecast such expenses due to uncertainty of future transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000087504526000068/0000875045-26-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000087504526000068/biib-20260701.htm
  HTML page:      https://secwatch.observer/filing/0000875045-26-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer